Back to Resources
Market Highlights
- Companies in the COVID-19 vaccine market used their social media platforms and websites to share regulatory and strategic advancements in Q3 2025, as major manufacturers secured approvals, expanded global access, and reinforced their public health commitments.
- Moderna received FDA approval for its updated 2025–2026 Spikevax and mNEXSPIKE vaccines, expanded manufacturing in the UK and Canada, and gained additional regulatory clearances in Canada and the EU.
- Novavax and Sanofi advanced their vaccine efforts, with Novavax receiving approvals in Japan and the US for its protein-based, non-mRNA COVID-19 vaccine.
- Pfizer and BioNTech announced positive Phase 3 results for their 2025–2026 COVID-19 vaccine, received FDA approval, and gained support from the CHMP. Pfizer was also recognized by the American Lung Association for its commitment to lung health and public education.
Questions about this SnapShot or other markets?
U.S. MARKETS
Christine Alongi
alongi@dtwresearch.com
GLOBAL MARKETS
Robin Cefalo
cefalo@dtwresearch.com
SOCIAL MEDIA MARKETS
Andrew Carney
carney@dtwresearch.com